<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2473">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366752</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0036</org_study_id>
    <nct_id>NCT04366752</nct_id>
  </id_info>
  <brief_title>Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy</brief_title>
  <acronym>THROMBOCOVID</acronym>
  <official_title>Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The understanding of haemostasis and inflammation cross-talk has gained considerable
      knowledge during the past decade in the field of arterial and venous thrombosis. Complex and
      delicately balanced interaction between coagulation and inflammation involve all cellular and
      humoral components. Elements of the coagulation system such as activated thrombin, fibrinogen
      or factor Xa may increase inflammation by promoting the production of pro-inflammatory
      cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant
      state amplifying the pathological process. Recent evidence supports inflammation as a common
      pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of
      inflammation-induced thrombosis.

      Patients with infection of COVID-19 and severe pneumoniae seem to have higher risk of
      thromboembolism. Very few data are available regarding the biological disorders of
      coagulation in these patients. Th purpose of this project is to analyze hemostasis and
      coagulation of patients with infection of COVID-19 and severe pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">September 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of thrombin time (in secondes) in Covid-19 patients with pneumonia admitted in ICU.</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU.</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>Pneumonia</condition>
  <condition>ARDS</condition>
  <condition>Hemostasis</condition>
  <condition>Coagulation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>venous ultrasound</intervention_name>
    <description>Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample for coagulation and hemostasis analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        every patient hospitalized in CHU Amiens medical ICU with pneumonia due to COVID-19
        infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients hospitalized in medical ICU with pneumonia due to COVID-19 infection

        Exclusion Criteria:

          -  patients&lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Slama, Pr</last_name>
      <phone>(33)3 22 08 78 41</phone>
      <email>slama.michel@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien Maizel, Pr</last_name>
      <phone>(33)3 22 08 78 07</phone>
      <email>maizel.julien@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Clement Brault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoann Zerbib, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Soudet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>pneumonia</keyword>
  <keyword>ARDS</keyword>
  <keyword>venous ultrasound</keyword>
  <keyword>hemostasis</keyword>
  <keyword>coagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

